Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.
Mohamed A EltelbaneiNoha A El-BassiounyMahmoud Salah AbdallaMohamed KhalafRehab H WeridaPublished in: BMC cancer (2024)
This study is registered on ClinicalTrials.gov under the registration number NCT05813132 ( https://clinicaltrials.gov/ct2/show/NCT05813132 ). (The first submitted registration date: is March 16, 2023).
Keyphrases
- high dose
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- computed tomography
- acute myeloid leukemia
- prognostic factors
- peritoneal dialysis
- diffuse large b cell lymphoma
- magnetic resonance imaging
- randomized controlled trial
- metabolic syndrome
- clinical trial
- patient reported outcomes
- adipose tissue
- platelet rich plasma
- weight loss